Patient characteristics
Patient . | Sex/age, y . | Vβ family . | Vβ+ clonal, % . | Vβ+ normal, range (%*) . | Absolute no. CD3+CD4+ Vβ+ . | CD4/CD8 ratio . | T/N/M . | Disease duration, mo . | Current disease . | Current therapy . | Previous therapy . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F/61 | Failed | – | – | – | 96 | T4/N0/M0 | 38 | Progress | 30 ECP + steroids syst | ECP, IFN, steroids syst |
| 2 | M/49 | Failed | – | – | – | 7 | T4/N1/M0 | 8 | Steady | 5 ECP + IFN + steroids syst | Chemotherapy |
| 3 | F/61 | 13.6 | 98 | 0.1-3.6 (1.5) | 1 348 | 16 | T4/N0/M0 | 46 | Steady | 30 ECP + IFN + steroids syst | ECP, IFN, steroids syst |
| 4 | M/73 | 2 | 83 | 0.7-20.5 (5.6) | 3 763 | 29 | T4/N0/M0 | 46 | Steady | 1 ECP + steroids syst | None |
| 5 | M/56 | 2 | 92 | 0.7-20.5 (5.6) | 3 162 | 96 | T4/N0/M0 | 10 | Steady | 1 ECP + steroids syst | Chemotherapy + steroids syst |
| 6 | F/58 | 7.2 | 95 | 0.1-5.7 (0.9) | 13 534 | 95 | T4/N1/M0 | 12 | Progress | 1 ECP + steroids syst | IFN + steroids syst + retinoid |
| 7 | M/45 | 5.1 | 68.5 | 1.2-6.1 (2.7) | 2 748 | 17 | T4/N0/M0 | 3 | Progress | 5 ECP + IFN | None |
| 8 | M/66 | 1 | 80 | 2.5-7.9 (3.8) | 2 590 | 15 | T4/N0/M0 | 13 | Progress | 1 ECP | IFN + steroids syst + PUVA |
| 9 | M/45 | 17 | 91 | 1.7-23.2 (4.7) | 2 915 | 24 | T4/N2/M0 | 0 | Beginning | 1 ECP + IFN | Chemotherapy + PUVA |
| 10 | M/60 | 2 | 54 | 0.7-20.5 (5.6) | 1 128 | 8 | T4/N0/M0 | 0 | Beginning | IFN | None |
| 11 | M/62 | Failed | – | – | – | 48 | T4/N1/M1 | 6 | Steady | 1 ECP + IFN | Chemotherapy |
| 12 | M/70 | 12 | 88 | 0.3-4.5 (1.3) | 9 685 | 18 | T4/N0/M0 | 0 | Beginning | 1 ECP + IFN | None |
Patient . | Sex/age, y . | Vβ family . | Vβ+ clonal, % . | Vβ+ normal, range (%*) . | Absolute no. CD3+CD4+ Vβ+ . | CD4/CD8 ratio . | T/N/M . | Disease duration, mo . | Current disease . | Current therapy . | Previous therapy . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F/61 | Failed | – | – | – | 96 | T4/N0/M0 | 38 | Progress | 30 ECP + steroids syst | ECP, IFN, steroids syst |
| 2 | M/49 | Failed | – | – | – | 7 | T4/N1/M0 | 8 | Steady | 5 ECP + IFN + steroids syst | Chemotherapy |
| 3 | F/61 | 13.6 | 98 | 0.1-3.6 (1.5) | 1 348 | 16 | T4/N0/M0 | 46 | Steady | 30 ECP + IFN + steroids syst | ECP, IFN, steroids syst |
| 4 | M/73 | 2 | 83 | 0.7-20.5 (5.6) | 3 763 | 29 | T4/N0/M0 | 46 | Steady | 1 ECP + steroids syst | None |
| 5 | M/56 | 2 | 92 | 0.7-20.5 (5.6) | 3 162 | 96 | T4/N0/M0 | 10 | Steady | 1 ECP + steroids syst | Chemotherapy + steroids syst |
| 6 | F/58 | 7.2 | 95 | 0.1-5.7 (0.9) | 13 534 | 95 | T4/N1/M0 | 12 | Progress | 1 ECP + steroids syst | IFN + steroids syst + retinoid |
| 7 | M/45 | 5.1 | 68.5 | 1.2-6.1 (2.7) | 2 748 | 17 | T4/N0/M0 | 3 | Progress | 5 ECP + IFN | None |
| 8 | M/66 | 1 | 80 | 2.5-7.9 (3.8) | 2 590 | 15 | T4/N0/M0 | 13 | Progress | 1 ECP | IFN + steroids syst + PUVA |
| 9 | M/45 | 17 | 91 | 1.7-23.2 (4.7) | 2 915 | 24 | T4/N2/M0 | 0 | Beginning | 1 ECP + IFN | Chemotherapy + PUVA |
| 10 | M/60 | 2 | 54 | 0.7-20.5 (5.6) | 1 128 | 8 | T4/N0/M0 | 0 | Beginning | IFN | None |
| 11 | M/62 | Failed | – | – | – | 48 | T4/N1/M1 | 6 | Steady | 1 ECP + IFN | Chemotherapy |
| 12 | M/70 | 12 | 88 | 0.3-4.5 (1.3) | 9 685 | 18 | T4/N0/M0 | 0 | Beginning | 1 ECP + IFN | None |
According to the EORTC classification, all patients had SS.
ECP indicates extracorporeal photopheresis; IFN, interferon α; PUVA, psoralens ultraviolet A; syst, systemic; and progress, that disease is progressing.
The percentage (range + median) of polyclonal TCR Vβ+ T cells expressing the indicated TCR Vβ gene observed in healthy controls